A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Recruiting now · Phase 3

Conditions studied: Varicella (Chickenpox), Chickenpox Vaccine

In brief

This clinical study aims to evaluate the safety and immune response of MG1111, in healthy children compared to VARIVAX. The study will follow participants for 42 days after receiving two doses, with additional follow-ups for up to 10 years to monitor varicella infection.

Key facts

Study ID

NCT07054099

Run by

GC Biopharma Corp

People needed

474

Starts

2026-03-17

Expected to finish

2036-07-01

Last updated by the study team

2026-04-17

Who can join

Age: 1 and older, up to 12. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participant must be 12 months to 12 years of age, inclusive, at the time of signing the informed consent or assent.
• Participant is overtly healthy as determined by the investigator

You may not qualify if…

• Participants with a history of exposure to varicella through contact with a varicella patient at home, school, or childcare facility within 4 weeks before Screening
• Participants with a history of varicella infection and varicella vaccine, either licensed or investigational, and either standalone or any combination, such as MMRV
• Participants with acute moderate or severe infection with or without fever at the time of dosing
• Participants who have had any suspected allergy symptoms, such as systemic rash, during the 72 hours before each administration of investigational product

Where it is running

• Srinagarind Hospital — Khon Kaen, Changwat Khon Kaen, Thailand (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.